Matthew Hebden Porteus is Sutardja Chuk Professor of Definitive and Curative Medicine at Stanford University.^[1] In 2003, as a postdoctoral fellow in David Baltimore's lab at the California Institute of Technology, Porteus was the first to demonstrate precise gene editing in human cells using chimeric nucleases.^[2]

He graduated magna cum laude from Harvard University and completed his MD and PhD at Stanford University.^[3] For his post-doctoral work he trained with David Baltimore at MIT and Caltech.^[3] He is a scientific founder of CRISPR Therapeutics and an academic founder of Graphite Bio.^[4][5]

He has an h-index of 69 according to Google Scholar.^[6]